A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer

Abstract Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose (RPTD) for the combination of capecita...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: John H. Strickler, Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S. David Hsu, S. Yousuf Zafar, Michael A. Morse, David Z. Chang, James L. Wells, Kimberly L. Blackwell, P. Kelly Marcom, Christy Arrowood, Emily Bolch, Sherri Haley, Fatima A. Rangwala, Ace J. Hatch, Andrew B. Nixon, Herbert I. Hurwitz
Format: Artigo
Langue:Inglês
Publié: BMC 2019-11-01
Collection:BMC Cancer
Sujets:
Capecitabine
Ziv-aflibercept
Metastatic colorectal cancer
Advanced solid tumors
Accès en ligne:http://link.springer.com/article/10.1186/s12885-019-6234-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires